Telix Pharmaceuticals stock
Price history
−5.76% over the period1 year: from $14.06 (November 18, 2025) to $13.25 (November 18, 2026), −5.76%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 18, 2026 | $13.25 |
| October 30, 2026 | $13.13 |
| September 30, 2026 | $15.72 |
| August 31, 2026 | $15.36 |
| July 31, 2026 | $14.21 |
| June 30, 2026 | $16.58 |
| May 29, 2026 | $13.03 |
| April 30, 2026 | $15.00 |
| March 31, 2026 | $13.66 |
| February 27, 2026 | $10.00 |
| January 30, 2026 | $10.55 |
| December 31, 2025 | $11.20 |
| November 28, 2025 | $15.22 |
| November 18, 2025 | $14.06 |
At a glance
The company
Develops therapeutic and diagnostic radiopharmaceuticals for cancer treatment and diagnosis, with lead candidates in prostate cancer, kidney cancer, and glioblastoma
Latest results
Quarter to September 30, 2025 · EPS -$0.14 (estimate $0.08)
TickerLandia's take on Telix Pharmaceuticals
- Pricier than similar companies: trailing 12-month P/E 89 vs 70 (+27%) in a group of 6.
- Strong point: Growth (45/100 in its group). Weak point: Financial strength (15/100).
- “Most upside for analysts” (Australia): No. 6 of 136.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−27.28% from the 52-week high
Analysts · 12 analysts
Average target$24.17+82.42% vs. price
Buy 11 · Hold 1 · Sell 0 · Buy
TickerLandia Fingerprint: Telix Pharmaceuticals
Compared with similar companies: very low financial strength.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Pricehigh63
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 69.6 83 P/E (trailing 12 months) 88.9 81 Price/book 6.53 59 Price/sales 5.07 27 Profitabilitylow36
How much it earns on revenue and capital.
Metric Value Position in group Net margin 3.8% 39 ROA 2.7% 44 Operating margin 6.2% 35 Gross margin 47.6% 20 ROE 7.4% 41 Earnings stabilitylow33
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 476.4% 23 Loss-making yearscounts in reverse: lower means more earnings stability 3 of 5 annual reports 43 Growthaverage45
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −1,652.47% 1 Revenue growth (year over year) +22.30% 53 Average revenue growth (3 years) +94.60% 82 Financial strengthvery low15
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 1.40 32 Current ratio 2.01 19 Net debt/EBITDAcounts in reverse: lower means more financial strength 10.0 1 Debt/equitycounts in reverse: lower means more financial strength 1.19 6 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumweak32
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −19.28% 16 Relative strength (6 months) −11.04% 32 1-year return −5.76% 35 Distance from 200-day average −6.82% 45 Riskhigh66
How much the price swings.
Metric Value Position in group Volatility (60 days) 55.4% 77 Beta (1 year) 0.80 54 Maximum drawdown (12 months) 43.6% 66
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Telix Pharmaceuticals is pricier than similar companies
Telix Pharmaceuticals's P/E (trailing 12 months): 88.9, +27% against the median of a group of 6 similar companies (69.8).
Compared with 6 similar companies
| Metric | Telix Pharmaceuticals | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 88.9 | Middle | |
| Operating margin | 6.2% | Middle | |
| ROE | 7.4% | Middle | |
| Debt/equity | 1.19 | High | |
| Price/book | 6.53 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Telix Pharmaceuticals. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$477.35M
Latest quarter · Q2 2026
Net income
$38.33M
Latest quarter · Q2 2026
Quarterly net margin
8.0%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $4.52B
- P/E
- 88.9
- EPS
- $0.15
- Volume
- 1.43M
- Daily trading
- €19.26M
- Dividend yield
- 0.00%
How Telix Pharmaceuticals is changing
All resultsRevenue grew 188.7% a year on average over the last 5 years
Operating margin rose from −46.3% to 2.4%
Less cash than profit: free cash flow equal to -54% of net income
Returns
Telix Pharmaceuticals returns
$1,000 invested in Telix Pharmaceuticals 5 years ago, on November 18, 2021, would be worth $1,898 today: +89.83% in total, +13.68% per year. This is the price return only: dividends are excluded.
| Period | Telix Pharmaceuticals | S&P/ASX 200 | $1,000 becomes |
|---|---|---|---|
| 1 month | −13.96% | +0.42% | $860 |
| 6 months | −7.08% | +4.44% | $929 |
| Year to date | +18.30% | +1.94% | $1,183 |
| 1 year | −5.76% | +4.89% | $942 |
| 3 years | +45.13% | +25.85% | $1,451 |
| 5 years | +89.83% | +20.38% | $1,898 |
Over the last 6 months it has done better than 12% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Telix Pharmaceuticals: technical analysis
Telix Pharmaceuticals shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 57.5% below its all-time closing high ($31.14, February 25, 2025).
- Trend
- No clear trend
- RSI (14 sessions)
- 40
- Between 30 and 70
- vs 200-session average
- −6.82%
Active signals
The price is moving in an unusually narrow range compared with the last year.
Support and resistance
Price areas where Telix Pharmaceuticals has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$15.45+16.60%2 touches, last on September 11, 2026
- Resistance$14.94+12.78%3 touches, last on October 2, 2026
- Resistance$14.00+5.64%3 touches, last on August 3, 2026
- Last price$13.25
- Support$12.08−8.83%2 touches, last on June 3, 2026
- Support$10.89−17.83%2 touches, last on February 23, 2026
Volatility and risk
Over the last year it has moved less than the S&P/ASX 200.
- Beta (1 year) vs S&P/ASX 200
- 0.80
- Volatility (60 sessions, annualised)
- 55.4%
- Largest fall in the last year
- −43.59%
In session, November 18, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Telix Pharmaceuticals: seasonality
Average monthly price change over 9 years
Over the last 9 years, the strongest month for Telix Pharmaceuticals has been November: +17.50% on average, positive in 6 years out of 8. The weakest has been February: −5.20% on average, positive in 1 years out of 9.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.42% | −2.48% | 4 of 9 |
| February | −5.20% | −3.00% | 1 of 9 |
| March | +3.17% | +3.62% | 5 of 9 |
| April | +13.89% | +9.81% | 8 of 9 |
| May | +7.90% | +9.52% | 6 of 9 |
| June | +6.64% | −2.79% | 4 of 9 |
| July | +4.58% | +0.62% | 5 of 9 |
| August | +4.21% | −2.04% | 4 of 9 |
| September | −0.93% | +0.61% | 5 of 9 |
| October | +2.90% | +0.96% | 6 of 9 |
| November | +17.50% | +7.83% | 6 of 8 |
| December | −2.40% | −1.22% | 2 of 9 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Telix Pharmaceuticals and its competitors
Telix Pharmaceuticals develops and commercializes radiopharmaceuticals, both therapeutic and diagnostic, and its largest segment is Precision Medicine, built around imaging agents such as Illuccix and Gozellix for prostate cancer. Its pipeline includes the lutetium-labeled radio antibody-drug conjugate TLX591, which is in a Phase 3 trial for advanced prostate cancer, along with candidates for kidney cancer, glioblastoma, soft tissue sarcoma and bone metastases.
- Headquarters
- North Melbourne, Australia
- Employees
- 1,120
- Founded
- 2015
- Chief executive
- Christian Behrenbruch
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Telix PharmaceuticalsTLX | $3.04B | 6.2% | 88.9 | −7.08% |
| InSilico Medicine Cayman TopCo3696 | $2.8B | 26.6% | — | −36.01% |
| 3SBio1530 | $4.56B | 60.3% | 3.90 | −31.48% |
| Neuren PharmaceuticalsNEU | $1.96B | 19.9% | 153.2 | +80.28% |
| Metis TechBio7666 | $1.7B | -89.6% | — | −70.16% |
| MesoblastMSB | $1.65B | -42.6% | — | −12.75% |
Same industry or related industries, similar size. Compare Telix Pharmaceuticals with its competitors · Full profile
